Hydrocephalus Clinical Trials

Find Hydrocephalus Clinical Trials Near You

Detection of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Flow Detection Device During Open and Closed Shunt Periods

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is evaluating a new, noninvasive device designed to detect whether cerebrospinal fluid (CSF) is flowing through a surgically implanted shunt. CSF shunts are commonly used to treat hydrocephalus, but it can be difficult to tell whether a shunt is working properly without invasive testing or imaging that does not directly measure flow. The study device is a small, wireless sensor placed on the skin over the shunt tubing, typically near the collarbone. It uses gentle, controlled warmth to measure temperature changes that indicate whether fluid is flowing inside the shunt. The device does not break the skin and does not change a participant's medical care. This study will enroll children and adults who already have a CSF shunt and who do not have new or worsening symptoms of shunt malfunction. All participants will have a measurement taken while their shunt valve is at its usual prescribed setting. Some participants with programmable shunt valves will also have a second measurement taken after their valve is temporarily adjusted to a setting intended to stop or greatly reduce flow (virtual off). After this measurement, the valve will be returned to its prescribed setting. The study device results will not be shown to participants or their medical providers and will not be used to make treatment decisions. The goal of the study is to determine how well the device can distinguish between shunts that are allowing flow and those that are not. Participants will be monitored for a short period after device use and, if applicable, after any valve adjustment. The main risks of participation are mild skin irritation from the adhesive or temporary symptoms related to valve adjustment. Participants are not expected to receive a direct medical benefit, but the information gained may help improve future diagnosis of shunt function.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

‣ Inclusion and Exclusion Criteria for Roll-In Subjects Inclusion criteria

⁃ Existing ventricular CSF shunt with an available virtual off setting which can be programmed noninvasively

⁃ Region of intact skin overlying an unambiguously identifiable palpable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device

⁃ Signed informed consent by subject or a parent or legal guardian, health care agent, or surrogate decision maker (according to local statutes)

⁃ Subject-reported or documented history of successful valve adjustment(s)

‣ Inclusion and Exclusion Criteria for Main Study Subjects

⁃ Existing ventricular CSF shunt

⁃ Region of intact skin overlying an unambiguously identifiable palpable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device

⁃ Signed informed consent by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes)

‣ Subjects with planned virtual off measurement:

• Existing ventricular CSF shunt with an available virtual off setting which can be programmed noninvasively

‣ Subjects with planned adjustment to the virtual off setting only:

• Subject-reported or documented history of successful valve adjustment(s)

Locations
United States
Illinois
OSF Healthcare
RECRUITING
Peoria
Contact Information
Primary
Anna Somera
info@rhaeos.com
855-814-3569
Time Frame
Start Date: 2026-01-27
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 55
Treatments
Other: CSF Shunt Flow Assessment with Wireless Thermal Device
Participants undergo noninvasive assessment of cerebrospinal fluid (CSF) shunt flow using a wireless thermal flow detection device placed on the skin overlying the shunt tubing. All participants have a measurement performed at their prescribed shunt valve setting. Participants with programmable valves capable of a manufacturer-reported virtual off setting may undergo an additional measurement after temporary valve adjustment to reduce or stop CSF flow, followed by return of the valve to the prescribed setting. Device results are encoded and blinded to participants and clinical staff and are not used for clinical decision-making. Participants are monitored for adverse events during and after device use.
Related Therapeutic Areas
Sponsors
Leads: Rhaeos, Inc.

This content was sourced from clinicaltrials.gov